Last reviewed · How we verify

Incretin Effect — Competitive Intelligence Brief

Incretin Effect (Incretin Effect) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Incretin-based therapy (mechanism class). Area: Diabetes.

marketed Incretin-based therapy (mechanism class) GLP-1 receptor and/or GIP receptor Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Incretin Effect (Incretin Effect) — University of Campania Luigi Vanvitelli. The incretin effect enhances insulin secretion in response to oral glucose intake by stimulating incretin hormones (GLP-1 and GIP) released from the intestine.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Incretin Effect TARGET Incretin Effect University of Campania Luigi Vanvitelli marketed Incretin-based therapy (mechanism class) GLP-1 receptor and/or GIP receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Incretin-based therapy (mechanism class) class)

  1. University of Campania Luigi Vanvitelli · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Incretin Effect — Competitive Intelligence Brief. https://druglandscape.com/ci/incretin-effect. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: